ReP USP - Resultado da busca

Artigo de periodico
Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases (2022)
Aikawa, Nadia Emi; Kupa, Leonard de Vinci Kanda; Medeiros-Ribeiro, Ana Cristina; Saad, Carla Goncalves Schahin; Pereira, Rosa Maria Rodrigues ; Shinjo, Samuel Katsuyuki ; Sartori, Ana Marli Christovam ; Antonangelo, Leila ; Silva, Clovis Artur Almeida da ; Bonfa, Eloisa Silva Dutra de Oliveira
Source: Annals of the rheumatic diseases. Unidade: FM
Subjects: VACINAÇÃO, DOENÇAS AUTOIMUNES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
AIKAWA, Nadia Emi et al. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. Annals of the rheumatic diseases, v. 81, n. 7, p. 1036-1043, 2022Tradução . . Disponível em: https://doi.org/10.1136/annrheumdis-2021-222096. Acesso em: 15 nov. 2024.
APA
Aikawa, N. E., Kupa, L. de V. K., Medeiros-Ribeiro, A. C., Saad, C. G. S., Pereira, R. M. R., Shinjo, S. K., et al. (2022). Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. Annals of the rheumatic diseases, 81( 7), 1036-1043. doi:10.1136/annrheumdis-2021-222096
NLM
Aikawa NE, Kupa L de VK, Medeiros-Ribeiro AC, Saad CGS, Pereira RMR, Shinjo SK, Sartori AMC, Antonangelo L, Silva CAA da, Bonfa ESD de O. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases [Internet]. Annals of the rheumatic diseases. 2022 ; 81( 7): 1036-1043.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1136/annrheumdis-2021-222096
Vancouver
Aikawa NE, Kupa L de VK, Medeiros-Ribeiro AC, Saad CGS, Pereira RMR, Shinjo SK, Sartori AMC, Antonangelo L, Silva CAA da, Bonfa ESD de O. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases [Internet]. Annals of the rheumatic diseases. 2022 ; 81( 7): 1036-1043.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1136/annrheumdis-2021-222096
Artigo de periodico
Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 (2022)
Shinjo, Samuel Katsuyuki ; Souza, Fernando H. C. de; Borges, Isabela B. P; Santos, Alexandre M. Dos; Miossi, Renata; Misse, Rafael G; Medeiros-Ribeiro, Ana C; Kupa, Leonard de Vinci Kanda ; Silva, Clovis Artur Almeida da ; Bonfa, Eloisa Silva Dutra de Oliveira
Source: Rheumatology. Unidade: FM
Subjects: DOENÇAS AUTOIMUNES, VACINAS VIRAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SHINJO, Samuel Katsuyuki et al. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. Rheumatology, v. 61, n. 8, p. 3351-3361, 2022Tradução . . Disponível em: https://doi.org/10.1093/rheumatology/keab773. Acesso em: 15 nov. 2024.
APA
Shinjo, S. K., Souza, F. H. C. de, Borges, I. B. P., Santos, A. M. D., Miossi, R., Misse, R. G., et al. (2022). Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. Rheumatology, 61( 8), 3351-3361. doi:10.1093/rheumatology/keab773
NLM
Shinjo SK, Souza FHC de, Borges IBP, Santos AMD, Miossi R, Misse RG, Medeiros-Ribeiro AC, Kupa L de VK, Silva CAA da, Bonfa ESD de O. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 [Internet]. Rheumatology. 2022 ; 61( 8): 3351-3361.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1093/rheumatology/keab773
Vancouver
Shinjo SK, Souza FHC de, Borges IBP, Santos AMD, Miossi R, Misse RG, Medeiros-Ribeiro AC, Kupa L de VK, Silva CAA da, Bonfa ESD de O. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 [Internet]. Rheumatology. 2022 ; 61( 8): 3351-3361.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1093/rheumatology/keab773
Artigo de periodico
Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study (2022)
Aikawa, Nadia E; Kupa, Leonard de Vinci Kanda ; Pasoto, Sandra Gofinet; Shinjo, Samuel Katsuyuki ; Pereira, Rosa Maria Rodrigues ; Sartori, Ana Marli Christovam ; Duarte, Alberto José da Silva; Antonangelo, Leila ; Sabino, Ester Cerdeira ; Menezes, Paulo Rossi ; Kallas, Esper Georges ; Silva, Clovis Artur Almeida da ; Bonfa, Eloisa Silva Dutra de Oliveira
Source: Lancet rheumatology. Unidade: FM
Subjects: IMUNOGENÉTICA, COVID-19, SISTEMA IMUNE, IMUNOGENICIDADE DA VACINA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
AIKAWA, Nadia E et al. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. Lancet rheumatology, v. 4, n. 2, p. E113-E124, 2022Tradução . . Disponível em: https://doi.org/10.1016/S2665-9913(21)00327-1. Acesso em: 15 nov. 2024.
APA
Aikawa, N. E., Kupa, L. de V. K., Pasoto, S. G., Shinjo, S. K., Pereira, R. M. R., Sartori, A. M. C., et al. (2022). Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. Lancet rheumatology, 4( 2), E113-E124. doi:10.1016/S2665-9913(21)00327-1
NLM
Aikawa NE, Kupa L de VK, Pasoto SG, Shinjo SK, Pereira RMR, Sartori AMC, Duarte AJ da S, Antonangelo L, Sabino EC, Menezes PR, Kallas EG, Silva CAA da, Bonfa ESD de O. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study [Internet]. Lancet rheumatology. 2022 ; 4( 2): E113-E124.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1016/S2665-9913(21)00327-1
Vancouver
Aikawa NE, Kupa L de VK, Pasoto SG, Shinjo SK, Pereira RMR, Sartori AMC, Duarte AJ da S, Antonangelo L, Sabino EC, Menezes PR, Kallas EG, Silva CAA da, Bonfa ESD de O. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study [Internet]. Lancet rheumatology. 2022 ; 4( 2): E113-E124.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1016/S2665-9913(21)00327-1

USP Schools

ReP

Filtros

Departament

Authors

USP affiliated authors

Subjects

Funding Agencies